172 related articles for article (PubMed ID: 26341695)
1. A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging.
Satterlee AB; Yuan H; Huang L
J Control Release; 2015 Nov; 217():170-82. PubMed ID: 26341695
[TBL] [Abstract][Full Text] [Related]
2. Chemoradiation therapy using cyclopamine-loaded liquid-lipid nanoparticles and lutetium-177-labeled core-crosslinked polymeric micelles.
You J; Zhao J; Wen X; Wu C; Huang Q; Guan F; Wu R; Liang D; Li C
J Control Release; 2015 Mar; 202():40-8. PubMed ID: 25637565
[TBL] [Abstract][Full Text] [Related]
3. Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform.
Satterlee AB; Huang L
Theranostics; 2016; 6(7):918-29. PubMed ID: 27217828
[TBL] [Abstract][Full Text] [Related]
4. Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy.
Satterlee AB; Rojas JD; Dayton PA; Huang L
Theranostics; 2017; 7(2):253-269. PubMed ID: 28042332
[TBL] [Abstract][Full Text] [Related]
5. Preclinical efficacy of hK2 targeted [
Timmermand OV; Elgqvist J; Beattie KA; Örbom A; Larsson E; Eriksson SE; Thorek DLJ; Beattie BJ; Tran TA; Ulmert D; Strand SE
Theranostics; 2019; 9(8):2129-2142. PubMed ID: 31149033
[TBL] [Abstract][Full Text] [Related]
6. In vivo evaluation of PEGylated ⁶⁴Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT.
Petersen AL; Henriksen JR; Binderup T; Elema DR; Rasmussen PH; Hag AM; Kjær A; Andresen TL
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):941-952. PubMed ID: 26646780
[TBL] [Abstract][Full Text] [Related]
7. A Proof-of-Concept Study on the Theranostic Potential of
Chen X; Tan F; Liang R; Liao J; Yang J; Lan T; Yang Y; Liu N; Li F
Chemistry; 2024 Feb; 30(9):e202303298. PubMed ID: 38050716
[TBL] [Abstract][Full Text] [Related]
8. Tumoral fibrosis effect on the radiation absorbed dose of (177)Lu-Tyr(3)-octreotate and (177)Lu-Tyr(3)-octreotate conjugated to gold nanoparticles.
Azorín-Vega EP; Zambrano-Ramírez OD; Rojas-Calderón EL; Ocampo-García BE; Ferro-Flores G
Appl Radiat Isot; 2015 Jun; 100():96-100. PubMed ID: 25305748
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of Lys¹(α,γ-Folate)Lys³(¹⁷⁷Lu-DOTA)-Bombesin(1-14) as a potential theranostic radiopharmaceutical for breast cancer.
Aranda-Lara L; Ferro-Flores G; Azorín-Vega E; Ramírez FM; Jiménez-Mancilla N; Ocampo-García B; Santos-Cuevas C; Isaac-Olivé K
Appl Radiat Isot; 2016 Jan; 107():214-219. PubMed ID: 26545016
[TBL] [Abstract][Full Text] [Related]
10. Proof of Therapeutic Efficacy of a
Schulz J; Rohracker M; Stiebler M; Goldschmidt J; Stöber F; Noriega M; Pethe A; Lukas M; Osterkamp F; Reineke U; Höhne A; Smerling C; Amthauer H
J Nucl Med; 2017 Jun; 58(6):936-941. PubMed ID: 28254866
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
12. [
Schottelius M; Osl T; Poschenrieder A; Hoffmann F; Beykan S; Hänscheid H; Schirbel A; Buck AK; Kropf S; Schwaiger M; Keller U; Lassmann M; Wester HJ
Theranostics; 2017; 7(9):2350-2362. PubMed ID: 28744319
[No Abstract] [Full Text] [Related]
13. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
[TBL] [Abstract][Full Text] [Related]
14. Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with (177)Lu and Conjugated to Peptides.
Ferro-Flores G; Ocampo-García BE; Santos-Cuevas CL; de María Ramírez F; Azorín-Vega EP; Meléndez-Alafort L
Curr Radiopharm; 2015; 8(2):150-9. PubMed ID: 25771363
[TBL] [Abstract][Full Text] [Related]
15. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
Persson M; Rasmussen P; Madsen J; Ploug M; Kjaer A
Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362
[TBL] [Abstract][Full Text] [Related]
16. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
17. Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer.
Dho SH; Kim SY; Chung C; Cho EH; Lee SY; Kim JY; Kim LK; Min SW; Lee J; Jung SH; Lim JC
Sci Rep; 2018 Jun; 8(1):8960. PubMed ID: 29895866
[TBL] [Abstract][Full Text] [Related]
18. Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.
Timmermand OV; Tran TA; Strand SE; Axelsson J
J Nucl Med; 2015 Mar; 56(3):444-9. PubMed ID: 25655628
[TBL] [Abstract][Full Text] [Related]
19. Radiometallic Complexes of DO3A-Benzothiazole Aniline for Nuclear Medicine Theranostics.
Park JA; Lee JW; Kim HK; Shin UC; Lee KC; Kim TJ; Chang Y; Kim KM; Kim JY; Lee YJ
Mol Pharm; 2018 Mar; 15(3):1133-1141. PubMed ID: 29381860
[TBL] [Abstract][Full Text] [Related]
20. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
